| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3342195 | Autoimmunity Reviews | 2009 | 5 Pages |
Abstract
Recent experimental and clinical studies have placed new emphasis on the role of the innate immune system in SLE. Nucleic acid-containing immune complexes activate the innate response by engaging specific Toll-like receptors (TLRs) and promote the generation of autoantibodies. Pharmacologic modulation of TLR-directed pathways may offer new therapeutic approaches for the treatment of SLE.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Wan-Uk Kim, Antoine Sreih, Richard Bucala,